Surveillance and prevention of hepatitis B and C in Europe
This report on hepatitis B and C presents the results of a survey in all EU/EEA countries. Twenty-two of the surveyed countries have already implemented universal vaccination programmes on hepatitis B for infants and adolescents, and half of the surveyed countries conduct screening programmes for hepatitis C, primarily for injecting drug users and prison inmates. Data on HBV and HCV screening policies, both for the general population and high-risk groups, remain sparse.
The reports caution that predicting disease trends for viral hepatitis is extremely difficult as disease surveillance systems in Europe differ considerably. In addition, the asymptomatic nature of hepatitis C further complicates data interpretation.
Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA
6 May 2021 - This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.
Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings
6 May 2021 - This document outlines the public health considerations for the use of rapid antigen detection tests (RADTs), including self-test RADTs to detect SARS-CoV-2 in individuals in occupational settings in the European Union/European Economic Area (EU/EEA), and provides information on the use of such tests in an occupational safety and health at work context.
Guidance for representative and targeted genomic SARS-CoV-2 monitoring
3 May 2021 - This document offers practical guidance for EU/EEA Member States on implementing genomic SARS-CoV-2 surveillance. It also includes advice on how to estimate the number of sequenced samples needed to achieve various objectives, including the early detection of novel variants.